CURRENT PORTFOLIO
-
SiteOne Therapeutics, Inc. (Private), is developing novel non-opioid pain therapeutcs targeting the sodium ion channel 1.7 with high selectivity. SiteOne also has programs in long acting analgesics and occular pain based on Nav 1.7
-
AN2 Therapeutics, Inc. (Private), is developing a novel antibiotic therapy for a difficult to treat pulmonary infection. Phase III registration trials expected to commence in 2021.
-
Coaxis Medical, Inc. (Private), Has developed instruments and fixtures for tissue approximation and anastomosis in the minimally invasive surgical setting. Coaxis has the potential to significantly reduce procedure time and improve patency.
-
Cluain Eraird Equity Investors
Cluain Eraird Equity Investors, LLC (CE Equity) manages limited partnerships that invest in very small capitalization publicaly-traded U.S. companies. Mr. Sears is an advisor to CE Equity and through an affilated Trust is an investor in CE Equity and CE Equity - Very Small Cap U.S. Long, L.P.
-
UpStart Ventures LLC: Utah based UpStart Ventures is a seed/early stage venture firm. SCM is an advisor to UpStart Ventures, LLC.
Cellerant Therapeutics, Inc. (Private), is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008, is in Phase 3 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.
Sears Capital Management, Inc (SCMI) provides this data for informational purposes only. No warranties or representations are made about the suitability of these securities for investment by individusals or institutions. Descriptions contained herein have not been reviewed by the named companies and are solely attributable to SCMI.